Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that despite a high incidence of side effects, patients generally tolerated spironolactone while benefiting from its treatment effects for acne and hirsutism.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This study found that a thyroid hormone receptor ẞ subtype-selective thyromimetic was effective in promoting hair growth in mouse and monkey models when applied topically.

Finasteride sustained-release tablets are stable.

This abstract suggests that finasteride's suppression of DHT may link DHT to migraine causes, or it may benefit migraines by other finasteride properties like testosterone modulation, but reports no new empirical findings.

Stopping finasteride for male pattern hair loss changes neuroactive steroid levels in the brain and blood.

This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

This article discusses the author's experience with prescribing generic finasteride for hair restoration but reports no new clinical findings.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

This study found that both Diane 35 plus spironolactone and Diane 35 plus finasteride were equally effective and safe for treating hirsutism and acne in Indian women over a 12-month period.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This study found that finasteride has selective effects on oxidative stress and acetylcholinesterase activity in different brain regions in rats with thioacetamide-induced hepatic encephalopathy.

This study found that spironolactone reduced testosterone production and urinary 17-ketosteroid excretion, leading to a decrease in hair growth rate and a change in hair texture in women.

This review discusses spironolactone as an effective and potentially safer treatment for androgenic alopecia, particularly when used with minoxidil, but calls for more high-quality clinical trials.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

Dr. Mayer Brezis argues that a study by Wang et al. incorrectly concluded that finasteride does not cause depression or suicide, due to methodological flaws, and suggests halting its marketing under the precautionary principle.